Warning: The NCBI web site requires JavaScript to function. more...
Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs).
Schiff R, Chamness GC, Brown PH.
Breast Cancer Res. 2003;5(5):228-31. Epub 2003 Jul 28. Review.
Related citations
Prevention of breast cancer: current state of the science and future opportunities.
Uray IP, Brown PH.
Expert Opin Investig Drugs. 2006 Dec;15(12):1583-600. Review.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
New approaches to reverse resistance to hormonal therapy in human breast cancer.
Weinberg OK, Marquez-Garban DC, Pietras RJ.
Drug Resist Updat. 2005 Aug;8(4):219-33. Epub 2005 Jul 27. Review.
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ, Johnston SR, Howell A.
Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Wu K, Brown P.
J Natl Cancer Inst. 2003 Jun 4;95(11):766-7. Review. No abstract available.
Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way?
Johnston SR.
Breast Cancer Res. 2005;7(3):119-30. Epub 2005 Apr 6. Review.
Prevention of breast cancer using SERMs and aromatase inhibitors.
Strassmer-Weippl K, Goss PE.
J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):5-18. Review.
Inhibition of aromatase: insights from recent studies.
Santen RJ.
Steroids. 2003 Sep;68(7-8):559-67. Review.
Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
Labrie F.
Endocr Relat Cancer. 2006 Jun;13(2):335-55. Review.
Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF.
Cancer Treat Rev. 2004 Dec;30(8):695-706. Review.
Chemoprevention with aromatase inhibitors--trial strategies.
Goss PE, Strasser K.
J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):143-9. Review.
Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD, Wood ME, Muss HB.
Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4. Review.
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A.
Clin Cancer Res. 2007 May 1;13(9):2751-7.
[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Fodor J.
Orv Hetil. 2006 Jan 22;147(3):121-5. Review. Hungarian.
The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
Brodie AH, Jelovac D, Long B.
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):283-8.
Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J, Sommer A.
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):191-200. Epub 2005 Jan 28.
Challenges in the endocrine management of breast cancer.
Mouridsen HT, Rose C, Brodie AH, Smith IE.
Breast. 2003 Aug;12 Suppl 2:S2-19. Review.
Aromatase inhibitors and breast cancer.
Miller WR.
Minerva Endocrinol. 2006 Mar;31(1):27-46. Review.
The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.
Tonetti DA, Jordan VC.
J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):401-13. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on